Feasibility and early outcome of high-dose-rate Ir-192 brachytherapy as monotherapy in two fractions within 1 day for high-/very high-risk prostate cancer.
The aim of the present study was to evaluate the feasibility and preliminary outcomes of high-dose-rate (HDR)-brachytherapy as a monotherapy in two fractions within 1 day for localized prostate cancer, including high-/very high-risk cases. Among the 68 patients treated with HDR monotherapy between July 2011 and December 2014, 65 had a minimal follow-up of 12 months without adjuvant androgen deprivation therapy and were enrolled in the present study [42/65 (64.6%) exhibited high-/very high-risk diseases]. HDR monotherapy was performed in two fractions with a minimal interval of 6 h and the prescribed dose was 13.5 Gy (×2). Adverse events (AEs) were assessed using Common Terminology Criteria for Adverse Events (version 4; http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40), and biochemical failure was assessed by the Phoenix definition. The median follow-up time was 30.1 months. The majority of patients had Grade 0-1 acute AEs. Four patients (6.2%) exhibited urinary retention, requiring a Foley catheter. Grade 3 acute AEs occurred at a frequency of 3.1% and hematuria at 1.5%. The majority of patients also exhibited Grade 0-1 chronic AEs. Grade 3 chronic AEs occurred at a frequency of 1.5% and urethral stricture at 1.5%, for which endoscopic treatment was indicated. Acute and chronic gastrointestinal AEs were uncommon, and no Grade 3 or above AEs developed. Biochemical failure occurred in 4 patients who all exhibited high-/very high-risk diseases. Kaplan-Meier estimated that 3 year biochemical failure-free survival was 91.6% overall and 88.0% in high-/very high-risk cases. The present two-fraction 1 day HDR monotherapy is feasible with minimal AEs and achieved acceptable biochemical control of localized prostate cancer, including high-/very high-risk cases, although long-term follow-up is required.
Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
Shingo
S
Ashida
Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
Ichiro
I
Yamasaki
Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
Kenji
K
Tamura
Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
Tsutomu
T
Shimamoto
Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
Keiji
K
Inoue
Department of Diagnostic Radiology and Radiation Oncology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
Shinji
S
Kariya
Department of Diagnostic Radiology and Radiation Oncology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
Kana
K
Kobayashi
Department of Diagnostic Radiology and Radiation Oncology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
Takuji
T
Yamagami
Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
Taro
T
Shuin
adverse event; high-dose-rate brachytherapy; high-risk prostate cancer; monotherapy; outcome